ALS Network Pushes Congress to Reauthorize ACT for ALS Act Through 2031 — ALS Network

Event summary

ALS Network supports reintroduction of the Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R.8205), led by Representatives Mike Quigley and Ken Calvert.
Legislation aims to reauthorize patient-centered approach to ALS research and therapy access through 2031.
Without reauthorization, programs expanding access to investigational therapies and research infrastructure will wind down.
ALS Network emphasizes urgency due to limited time and treatment options for ALS patients.

The big picture

The push for reauthorization of the ACT for ALS Act underscores the critical need for continued funding and coordination in ALS research. With limited treatment options and a rapidly progressing disease, sustained legislative support is essential to maintain momentum in the biotech ecosystem. The bipartisan backing of the legislation highlights its strategic importance in advancing patient-centered approaches to rare disease treatment.

What we're watching

Legislative Momentum: Whether Congress will act swiftly to reauthorize the ACT for ALS Act before current programs wind down.
Research Impact: How sustained funding will affect the pace of ALS treatment discovery and development.
Patient Access: The extent to which reauthorization will expand access to investigational therapies for ALS patients unable to participate in clinical trials.